INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

~ Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) ~ Cash and cash equivalents of $84.5 million on September 30th

Daniel Carlson

November 3, 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

rcube November 7, 2021 at 8:33 am

You need to login to view this content.

Reply
rcube November 7, 2021 at 8:17 am

You need to login to view this content.

Reply
evoltin November 3, 2021 at 6:38 pm

You need to login to view this content.

Reply
- Daniel Carlson November 4, 2021 at 9:01 am
  
  You need to login to view this content.
  
  Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.